Cosequin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cosequin

What is Cosequin? Identity and Pharmacological Class

Property Description
Active Ingredient Glucosamine hydrochloride (FCHG49), Sodium chondroitin sulfate (TRH122)
Form Chewable tablets, soft chews, capsules, powder, oral liquid
Pharmacological Class Nutraceutical; Conceptual Chondroprotective Agent
General Purpose Support and maintenance of joint structure and mobility
Origin Derived (from natural sources, standardized and proprietary)

Cosequin is classified as a nutraceutical and food supplement manufactured by Nutramax Laboratories Veterinary Sciences, Inc. It is recognized as the number one veterinarian recommended retail joint health supplement brand among small animal practitioners, underscoring its professional acceptance. This classification places it outside the strict regulatory category of pharmaceutical drugs, although similar preparations are sometimes classified as Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in international contexts. This oral combination product is designed for target audiences including dogs, cats, and horses, and is available in several dosage forms, such as tasty chewable tablets and soft chews, to facilitate administration.


Composition and General Purpose

The product's identity is defined by its two primary active ingredient(s): the proprietary Glucosamine hydrochloride (FCHG49) and Sodium chondroitin sulfate (TRH122). These specific forms are manufactured under proprietary specifications, a key differentiator intended to ensure batch-to-batch consistency that is often variable in non-standardized supplements. These compounds are structurally vital, as research indicates they act as fundamental precursors and structural components of cartilage. This means the preparation provides essential building blocks for maintaining healthy joint tissues.

The general purpose of Cosequin is to offer chondroprotective support to joint tissues, focusing on maintaining their structure and functional integrity. This is achieved by supplying the components necessary for the body to synthesize and maintain cartilage over time, thus supporting long-term joint function, comfort, and mobility.

Regulatory References

  1. NCCIH Glucosamine and Chondroitin

What side effects are possible with Cosequin?

Possible side effects and safety information

The safety profile for the active components of Cosequin—Glucosamine hydrochloride and Sodium chondroitin sulfate—is primarily derived from general safety advisories and data compiled by government health authorities for these ingredients. This profile differs from the comprehensive drug labeling (SmPC/FDA Prescribing Information) typical of regulated pharmaceuticals.

Documented Adverse Reactions and Frequencies

Adverse reactions associated with the components are generally mild and transient, primarily affecting the body's systems as follows:

System-Organ Class Common/Infrequent Reactions Serious Reactions (Rare/Not Known)
Gastrointestinal System Nausea, Diarrhea, Constipation, Stomach discomfort. Rare reports of liver injury/abnormal liver function tests.
Nervous System Headache.
Immune System Potential for Severe Allergic Reactions (hypersensitivity).

Safety Constraints and Special Populations

Official safety guidance highlights specific constraints and cautions regarding the use of these components. The product is contraindicated in individuals with a known hypersensitivity to Glucosamine or Chondroitin.

Caution is advised for several specific populations based on documented component risks:

  • Allergies: Individuals with a shellfish allergy should exercise caution, as Glucosamine is often derived from shellfish.
  • Metabolic Conditions: Caution is noted for individuals with diabetes due to the potential for effects on blood glucose levels.
  • Drug Interactions: There is a documented risk of an increased effect of blood thinners (anticoagulants) when used concurrently with the Chondroitin component, which may elevate the risk of bruising or bleeding.

Furthermore, use during pregnancy or lactation is generally discouraged due to a lack of sufficient reliable safety data.

Overdose and Emergency Response

Overdose and When to Seek Help

Cosequin is a brand name for a joint health supplement, typically containing glucosamine and chondroitin sulfate, and is primarily marketed for veterinary use. It is important to note that this product is generally categorized as a dietary supplement or nutraceutical and is not regulated by the U.S. Food and Drug Administration (FDA) as a prescription or over-the-counter drug.


Regulatory Overdose Profile

Official regulatory documents for supplements do not contain a standardized 'Overdose' section comparable to those for pharmaceuticals. The available information on overdose presentations is drawn primarily from clinical reports of excessive ingestion.

Documented Overdose Presentations

Symptoms associated with excessive intake, especially in animals, typically range from mild to severe and include vomiting, diarrhea, and lethargy. More serious consequences reported after significant over-supplementation include signs of hepatotoxicity (liver damage), severe hypernatremia (high sodium levels), and neurological issues such as disorientation and seizures.

Required Emergency Action

If an excessive amount of this supplement is suspected to have been ingested, or if symptoms such as severe gastrointestinal upset, allergic reactions, or neurological changes are observed, immediate contact with a medical professional (for human exposure) or a veterinarian/poison control center (for animal exposure) is required for guidance and treatment.

Therapeutic Uses of Cosequin

What Cosequin Treats: Main Uses and Benefits

Cosequin is commonly used to provide long-term supportive care for animals experiencing conditions characterized by periods of heightened symptoms related to joint health, such as Osteoarthritis. The product is applied across domains where additional symptomatic support is needed. These components are associated with maintaining healthy cartilage and joint health. The product is relevant for managing symptom clusters that interfere with daily functioning, such as physical stiffness, lameness, and joint discomfort.

The use is relevant for long-term support of functional stability for high-risk patient groups, including senior pets, large-breed dogs, and equine athletes. It is considered relevant for early support in conditions like hip dysplasia and may be applied in scenarios where additional management of discomfort is required following orthopedic surgery or injury, supporting functional stability during symptomatic phases.

In cats, Cosequin is applied as a complementary measure in the management of specific non-infectious conditions within Feline Lower Urinary Tract Disease (FLUTD), such as Feline Idiopathic Cystitis (FIC). The use is relevant for easing symptoms related to inflammatory or irritative states in the bladder. It may provide supportive relief when symptoms interfere with routine activities associated with recurrent lower urinary tract symptoms.


Quick Fact: Support for Functional Stability

Cosequin plays a role in managing symptoms that interfere with daily functioning, supporting functional stability during episodes of heightened discomfort related to chronic joint conditions, and is applied in addressing symptoms linked to organ-specific functional stress in cats.

Regulatory References

  1. Health Canada product information on Chondroitin and Glucosamine

Eligibility and Restrictions for Use

The eligibility profile for the active components of Cosequin (Glucosamine/Chondroitin) is determined by regulatory classifications concerning specific populations and health statuses.

Eligibility Scope

Category Eligibility Status (Official Regulatory Statement)
Allowed Population Adults aged 18 years and over (Human Glucosamine Analog).
Not Recommended/Prohibited Children and adolescents below 18 years; Women who are pregnant or breastfeeding.
Absolute Contraindications Patients with known hypersensitivity to Glucosamine or any excipients; individuals with an allergy to shellfish.

Age and Conditional Restrictions

Use of glucosamine is not recommended in persons under the age of 18 years as safety and efficacy have not been established in this age group.

Caution is advised for populations with existing conditions, as eligibility is conditional. This includes patients with impaired glucose tolerance (such as diabetes mellitus), where closer monitoring of blood sugar levels is recommended. Caution is also advised for asthmatic patients, and administration to those with severe hepatic or renal insufficiency should be under medical supervision, as specific studies are lacking. Use is not recommended during pregnancy or lactation due to inadequate data.

Connection to the overall eligibility profile

Official regulatory documents establish absolute prohibitions for individuals with allergies and define a lack of established safety for pediatric, pregnant, and lactating populations. Eligibility is therefore limited to adults and requires explicit caution or medical supervision based on a patient's underlying health status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cosequin's active components, Glucosamine and Sodium chondroitin sulfate, is primarily defined by pharmacodynamic effects with select pharmaceuticals, as documented by official health authorities.


Documented Interaction Patterns

Interaction Type Interacting Substance Official Regulatory Statement
Pharmacodynamic Potentiation Oral Anticoagulants (e.g., Warfarin) Co-administration is documented to increase the anticoagulant effect, leading to an elevated risk of bleeding or increased International Normalized Ratio (INR).
Exposure Modification Tetracycline (Antibiotic) The Glucosamine component is documented to increase the gastrointestinal absorption and subsequent plasma exposure of this antibiotic.

Interaction Context and Constraints

Official government documentation does not classify any medicinal product combinations as Contraindicated with Cosequin. Furthermore, the regulatory labeling does not include specific timing-separation rules (e.g., "administer four hours apart") or details regarding interactions mediated by hepatic CYP enzymes or drug transporters. The primary official constraint is the requirement for close monitoring and potential adjustment of the dose of co-administered oral anticoagulants, based on the documented risk of potentiation.

The overall profile is structured by these two specific pharmaceutical interactions, as no explicit restrictions are cited for use with food, alcohol, or other general supplements.

Mechanism of Action

Cosequin exerts its mechanism of action primarily through its active ingredients, glucosamine hydrochloride and chondroitin sulfate, which target chondrocyte function and inflammatory pathways within articular tissue. Glucosamine, an amino monosaccharide, serves as a molecular precursor for the synthesis of glycosaminoglycans (GAGs) and proteoglycans, which are structural macromolecules of the cartilage matrix. It is also proposed to modulate cellular signaling pathways. Specifically, glucosamine has been shown to inhibit the nuclear translocation of the NF-kappaB transcription factor, reducing the gene expression and production of pro-inflammatory mediators such as Interleukin-1beta (IL-1beta) and Nitric Oxide (NO). Chondroitin sulfate, a GAG itself, functions by inhibiting the activity and gene expression of catabolic enzymes, including Matrix Metalloproteinases (MMPs)—key enzymes involved in the degradation of the cartilage matrix. This dual interaction modifies the balance between matrix synthesis and degradation within the joint's cellular environment.

Dosage and Administration Information

How to Use Cosequin

Cosequin is administered via the oral route using its various forms, which include chewable tablets, soft chews, and powders. The administration protocol adheres to a standardized Two-Phase Regimen, which is the high-level dosing schedule defined by the product label. This regimen mandates an initial Loading Phase that utilizes a higher daily unit amount, typically for a period of four to six weeks, followed by a Maintenance Phase which continues with a lower daily dose for long-term supportive use.

The specific daily unit amount for both phases is rigorously weight and species-dependent, reflecting a tiered dosing approach based on the animal's body weight (e.g., dogs) or specific species (e.g., cats, horses). This classification serves as the high-level administration rule, substituting for human age-group adjustments. For ease of use, the product may be given with or without food. The full daily dose can be given at once or divided throughout the day. When using powdered formulations, official instructions guide users to mix the contents directly with the animal’s food to ensure complete consumption of the dosage. This sequence—starting high, transitioning low, and always correlating the dose to weight—constitutes the official procedural structure for product use.

Recent Clinical Evidence

Research evidence / Overview of studies for Cosequin


Evidence Base for Joint Support in Dogs with Osteoarthritis

Research examining Cosequin's components was focused primarily on adult dogs with confirmed Osteoarthritis (OA), a condition characterized by fluctuating or episodic manifestations of symptoms. Studies exploring this context include short-term and intermediate-term Randomized Controlled Trials (RCTs). In these trials, researchers examined outcomes related to physical discomfort and daily functioning over defined time intervals. Studies monitored patterns over the study period across various objective measures, like gait analysis, and veterinarian-assessed scores for physical discomfort.

However, the certainty surrounding the evidence remains low, and the findings were mixed across the published scientific literature. Studies often report that the results apply only to the populations studied, and that evidence quality varies across different proprietary preparations. There is limited information available for long-term outcomes, as the follow-up durations were limited.


Evidence for Use in Horses with Navicular Syndrome

Research examined Cosequin's components in horses with Navicular Syndrome, a condition marked by functional limitations and forelimb lameness. The existing evidence includes a limited number of placebo-controlled clinical trials. Studies explored outcomes related to physical discomfort, tracking changes in standardized lameness indices and overall clinical condition assessments over defined time intervals of a few weeks.


Evidence for Supportive Use in Cats with Feline Idiopathic Cystitis (FIC)

For cats experiencing symptoms linked to inflammatory or irritative states in the bladder, such as those seen in Feline Idiopathic Cystitis (FIC), research largely involves observational settings and clinical reports, rather than established controlled clinical trials. Studies have explored the potential supportive role by focusing on outcomes linked to inflammatory or irritative states, such as subjective symptom severity. The main limitation is the paucity of sufficiently powered, controlled research directly for this combination in cats with FIC.


Research Gaps and Areas of Uncertainty

Clinical research has focused heavily on short-term symptom changes. Due to the design of most existing trials, there is limited information for long-term outcomes or how observed patterns may persist with continued use. Long-term effects are not fully established. A major limitation is the inconsistency of findings and modest sample sizes in some research. Comparative evidence is lacking in certain animal populations, and data for certain groups remain insufficient.

Key Studies & References

  1. Efficacy of an oral nutraceutical for the treatment of canine osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Cosequin (FAQ)


Q: Is Cosequin actually intended for human use, given its popularity as a pet supplement?

A: Cosequin is manufactured and marketed as a veterinary supplement for animals. However, its active ingredients, glucosamine and chondroitin, are widely available in other products with regulatory labeling that is intended for human use as a dietary supplement. Therefore, the information provided here is based on the official guidelines for the human use of these core ingredients.

Q: How does the action of Cosequin's ingredients differ from a prescription joint pain reliever?

A: The ingredients in Cosequin are described as working at a structural level. They are considered molecular precursors, meaning they help provide the basic building blocks for cartilage components. This approach differs from most prescription pain relievers, which primarily work by blocking or reducing the transmission of pain signals.

Q: What is the typical timeframe for a person to expect any potential results from using Cosequin?

A: Studies and official product information for human glucosamine and chondroitin supplements indicate that these are generally slow-acting compounds. Some product information suggests that initial benefits might be noticeable around four weeks of consistent use.

Q: Is it necessary to inform a healthcare provider about using Cosequin before any scheduled surgery?

A: Official safety guidance indicates that individuals should consult their healthcare provider to determine if these ingredients need to be stopped before any scheduled procedure. This is primarily due to the documented risk that the chondroitin component can potentially interact with blood-thinning medications.

Q: Does the evidence indicate that Cosequin's ingredients can help with joint issues beyond the knee?

A: While research on these ingredients often concentrates on common areas like the knee joint, some evidence also explores effects in other joints. Studies related to the ingredients have reported findings related to osteoarthritis in areas such as the hand and the temporomandibular joint (TMJ).

Q: Is Cosequin described as safe for long-term daily use over many years?

A: Official sources indicate that Glucosamine sulfate has been studied and used for up to three years in most adults without major safety concerns being established. However, clinical studies providing reliable safety data for continuous long-term use extending beyond this period are not fully established in all regulatory literature.

Q: Why do some Cosequin formulas contain additional ingredients like MSM or manganese?

A: Regulatory labels for some glucosamine and chondroitin supplements often list additional ingredients such as MSM or Manganese Sulfate. These official documents confirm the presence of these compounds but do not explicitly state the specific reason for their inclusion in the formula.

Q: Can Cosequin's ingredients potentially affect eye pressure in someone with glaucoma?

A: Safety information associated with glucosamine advises caution in individuals with glaucoma. This caution is based on documented concerns that glucosamine might slightly increase the pressure inside the eye.

Q: Are Cosequin's ingredients intended to repair existing joint damage or only to maintain joint function?

A: The purpose of the active ingredients is described as providing structural components and general support. Their role is primarily focused on the long-term maintenance of healthy joint function, connective tissue, and cartilage.

Q: Do the ingredients in Cosequin provide immediate pain relief for joint discomfort?

A: The active compounds in Cosequin are typically studied for their potential slow-acting effects on joint symptoms over an extended period. They are not intended or described in official documentation as providing immediate, acute pain relief.

Q: Is the quality and purity of Cosequin's ingredients regulated by a specific government agency?

A: As a dietary supplement, the regulatory requirements for purity, potency, and strength are different from those applied to prescription medications. This means the government regulatory body does not mandate the same rigorous quality control standards as required for pharmaceutical drugs.

Q: Why are glucosamine and chondroitin typically combined in supplements like Cosequin?

A: Authoritative sources suggest that the compounds are often combined because their actions are thought to be complementary. Glucosamine works as a structural precursor, while chondroitin is described as helping to inhibit enzymes that degrade joint cartilage.

Q: Are there any precautions described for people with high blood pressure who use Cosequin's ingredients?

A: While there was once some concern regarding the ingredients and blood pressure, most recent research indicates that glucosamine does not appear to increase blood pressure. Individuals with high blood pressure are advised to discuss the use of any new supplement with a healthcare professional.

Q: What constitutes a serious or severe side effect that requires a person to stop using Cosequin?

A: Official warnings highlight that any severe adverse reactions, such as signs of allergic reaction or changes in heart rhythm, require immediate medical consultation and discontinuation of the product. Rare reports of liver injury have also been documented in the safety profile.

Q: If a person feels drowsy after taking Cosequin, is this a recognized side effect?

A: Drowsiness has been noted in the safety literature as a possible side effect of the active ingredients. This reaction is reported alongside other common but mild symptoms like headache and gastrointestinal discomfort.

Q: What is the difference between Cosequin and other widely available joint supplements?

A: Cosequin differentiates itself by specifying that it uses proprietary forms of its active ingredients: Glucosamine hydrochloride (FCHG49) and Sodium chondroitin sulfate (TRH122). This is intended by the manufacturer to help ensure consistency and quality across product batches.

Q: Is there any evidence that Cosequin ingredients affect cholesterol levels?

A: Safety information indicates that although there was previously some concern in the medical community, most clinical research shows that glucosamine does not appear to cause an increase in cholesterol levels.

Q: Does the research on Cosequin's ingredients suggest that it is effective for inflammatory types of arthritis?

A: The ingredients are known to exhibit certain anti-inflammatory mechanisms in the body. However, research into its effectiveness for inflammatory types of arthritis, such as rheumatoid arthritis, remains mixed and inconsistent across studies.

Q: Are Cosequin's active compounds naturally produced by the human body?

A: Yes, official documents describe that Glucosamine and Chondroitin are fundamental structural compounds. They are naturally found in the human body as components of the articular cartilage's extracellular matrix.

Q: Are there guidelines for managing common but bothersome side effects of Cosequin, like constipation?

A: General safety guidelines indicate that taking the product during or immediately after consuming a meal may help reduce the incidence of gastrointestinal upset, such as constipation or stomach discomfort.

Q: Is the form of glucosamine in Cosequin manufactured synthetically or derived from natural sources?

A: Glucosamine is frequently derived from natural sources. Specifically, it is often sourced from the shells of shellfish, such as crabs, shrimp, and lobsters, which is why an allergy warning for shellfish is necessary on product labels.

Q: Is there any described risk of overdose if a person accidentally takes an extra amount of Cosequin?

A: Warnings for products containing these ingredients advise that an accidental overdose requires immediate medical attention.

Q: Can Cosequin's ingredients affect the function of the kidneys or liver?

A: Official safety guidance advises caution for individuals with severe pre-existing hepatic (liver) or renal (kidney) insufficiency. Furthermore, rare reports of liver injury or abnormal liver function tests have been documented in the safety profile.

Q: Is Cosequin officially recommended for use in healthy individuals as a preventative measure?

A: Human dietary supplement labeling generally describes the product's purpose as helping to support and maintain healthy, mobile joint function. This purpose implies a general maintenance role that extends beyond only treating existing joint disease.

Q: Are the safety statements for Cosequin's ingredients based on short-term or long-term clinical data?

A: The available clinical research used to inform safety statements is primarily drawn from short-term and intermediate-term studies. The official literature notes that the long-term effects of continued, extended use are not yet fully established.

How should Cosequin be stored and disposed of?

Storage and Disposal of Cosequin

The storage and handling of Cosequin products must follow the conditions specified in the official labeling to maintain product stability and safety.

Storage Requirements

The product must be stored at room temperature in a cool, dry area and kept out of direct sunlight. To protect the contents from degradation and ensure freshness, the container's closure must be tightly or securely closed immediately after use. A primary safety instruction is to keep the product out of the reach of children at all times.

Disposal Instructions

For discarding expired or unused product, official guidance recommends using a community drug take-back program when possible. If a take-back program is unavailable, the product may be disposed of in household trash by mixing it with an unappealing substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cosequin found in:

A-Z Index: